Prior vaccination with rVSV-ZEBOV does not interfere with but improves efficacy of postexposure antibody treatment

• Published in: Nature communications Vol. 11; no. 1; pp. 3736 - 8
• Main Authors: Cross, Robert W., Bornholdt, Zachary A., Prasad, Abhishek N., Geisbert, Joan B., Borisevich, Viktoriya, Agans, Krystle N., Deer, Daniel J., Melody, Kevin, Fenton, Karla A., Feldmann, Heinz, Sprecher, Armand, Zeitlin, Larry, Geisbert, Thomas W.
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 27.07.2020; Nature Publishing Group; Nature Portfolio
• Subjects: 631/250/2152/2153/1291; 631/326/590/1867; 631/326/596/2042; 64; Animals; Antibodies; Antibodies, Monoclonal - administration & dosage; Antibodies, Monoclonal - immunology; Antibodies, Monoclonal - therapeutic use; Antibodies, Viral - administration & dosage; Antibodies, Viral - immunology; Antibodies, Viral - therapeutic use; Ebola Vaccines - immunology; Ebola virus; Ebolavirus; Glycoproteins; Hemorrhagic Fever, Ebola - immunology; Hemorrhagic Fever, Ebola - pathology; Hemorrhagic Fever, Ebola - prevention & control; Hemorrhagic Fever, Ebola - virology; Humanities and Social Sciences; Humans; Immunoglobulin G - blood; Immunoglobulin M - blood; Immunotherapy; Kaplan-Meier Estimate; Lethal dose; Macaca mulatta; Monkeys; Monoclonal antibodies; multidisciplinary; Post-Exposure Prophylaxis; Primates; Science; Science (multidisciplinary); Stomatitis; Treatment Outcome; Vaccination; Vaccines; Vesicular stomatitis Indiana virus - immunology; Viral diseases; Viral Load - immunology

A replication-competent vesicular stomatitis virus vaccine expressing the Ebola virus (EBOV) glycoprotein (GP) (rVSV-ZEBOV) was successfully used during the 2013-16 EBOV epidemic. Additionally, chimeric and human monoclonal antibodies (mAb) against the EBOV GP have shown promise in animals and human...